Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Incyte Corporation
Incyte Corporation
CTI BioPharma
CTI BioPharma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Mayo Clinic
OHSU Knight Cancer Institute